NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Medical Letter on the CDC & FDA

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Chemotherapy



Tentative FDA approval received for Ondanestron Hydrochloride



July 24th, 2005

Par Pharmaceutical Companies, Inc., (PRX) announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the company's abbreviated new drug application (ANDA) for ondansetron hydrochloride (HCl) orally disintegrating tablets (ODT) in 4 mg and 8 mg strengths.

GlaxoSmithKline currently markets ondansetron HCl ODT under the brand name Zofran ODT. The product is used for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, certain radiotherapies, and the prevention of postoperative nausea and/or vomiting. Annual U.S. sales of Zofran ODT are approximately $225 million.

Par's wholly owned...


Source: Medical Letter on the CDC & FDA (2005-07-24)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login